Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

BACKGROUND: Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5. OBJECTIVE: Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis. METHODS: In the RADIANCE Part A phase II study (NCT01628393), participants with relapsing...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Jeffrey A, Comi, Giancarlo, Arnold, Douglas L, Bar-Or, Amit, Selmaj, Krzysztof W, Steinman, Lawrence, Havrdová, Eva K, Cree, Bruce AC, Montalbán, Xavier, Hartung, Hans-Peter, Huang, Vivian, Frohna, Paul, Skolnick, Brett E, Kappos, Ludwig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681431/
https://www.ncbi.nlm.nih.gov/pubmed/30043658
http://dx.doi.org/10.1177/1352458518789884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681431/
https://www.ncbi.nlm.nih.gov/pubmed/30043658
http://dx.doi.org/10.1177/1352458518789884

Ejemplares similares